However, the emergence of novel agents targeting XPO1 and HOX, which influence the intranuclear relocation of mutated NPM1, offers new hope in treating this AML subtype [9,10,11,12,13,14,15,51,57,61,62,63]. This evidence concerns the gene NPM1 and acute myeloid leukemia.